期刊
MOLECULAR ONCOLOGY
卷 14, 期 7, 页码 1555-1568出版社
WILEY
DOI: 10.1002/1878-0261.12705
关键词
angiogenesis; biomarker; cancer; extra domain B; immunotherapy; targeted therapy
类别
资金
- ERC Advanced Grant (ERC-ADG-2015) [694812 - HYPOXIMMUNO]
- European Program H2020-2017 grant (ImmunoSABR) [733008]
- European Union's H2020 Research and Innovation Program Marie Sklodowska-Curie International Training Network (H2020-MSCA-ITN) grant (RADIATE) [642623]
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED-B and has shown therapeutic potential when combined with cytokines, such as IL-2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED-B targeting for the imaging and treatment of various types of cancer. ED-B-centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody-based targeted therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据